Business Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the company, compounded GLP-1 drugs and AI. Read the original report. Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn Articles You May Like Japanese automakers vulnerable to one-two punch of Iran war, yen rally The ‘20% rule’ behind Giorgos Tsetis’ blueprint for a new kind of family office Berkshire adds $17 billion to Alphabet stake Tariff bills across U.S. states mount as affordability and Trump head for midterm elections showdown Goldman’s latest cash cow is all about funding the AI infrastructure boom